DarioHealth (NASDAQ:DRIO) issued its earnings results on Tuesday. The company reported ($7.72) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($6.70), Fidelity Earnings reports. DarioHealth had a negative net margin of 234.63% and a negative return on equity of 216.56%.
Shares of NASDAQ DRIO opened at $3.50 on Friday. The business has a fifty day simple moving average of $7.85 and a 200 day simple moving average of $4.41. The company has a current ratio of 4.39, a quick ratio of 1.35 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $8.50 million, a price-to-earnings ratio of -0.39 and a beta of 0.21. DarioHealth has a one year low of $3.02 and a one year high of $18.60.
DRIO has been the subject of a number of recent research reports. Craig Hallum cut their target price on DarioHealth from $12.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday. ValuEngine lowered DarioHealth from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 6th.
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device.
Featured Article: What is the price-to-earnings growth (PEG) ratio?
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.